Comparison of the Real-World Reporting of Symptoms and Well-Being for the HER2-Directed Trastuzumab Biosimilar Ogivri With Registry Data for Herceptin in the Treatment of Breast Cancer: Prospective Observational Study (OGIPRO) of Electronic Patient-Reported Outcomes.
第一作者:
Andreas,Trojan
第一单位:
Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
作者:
DOI
10.2196/54178
PMID
38573759
发布时间
2024-04-21
- 浏览0
JMIR cancer
2024年10卷
e54178页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文